AstraZeneca has added WPP to the global creative roster of its massive oncology business following a competitive review.
Ad Age’s Post
More Relevant Posts
-
Pfizer revealed its oncology business plan during the recent #ASCO2024 meeting in Chicago. The company aims to have eight #blockbuster cancer drugs by as early as 2030, coming from its focused therapeutic areas of hematology, thoracic, breast, and genitourinary cancers. Following the reworking of Pfizer’s commercial infrastructure in which oncology became a separate division, accommodating the $43 billion acquisition Seagen (antibody-drug conjugate specialist) tie-up deal, the company is at the scale ‘it needs to be’ (according to Suneet Varma). The newly merged Oncology Commercial and Medical team will utilize Pfizer’s publicist and digital tools to enhance Seagen’s products, such as the Astellas Pharma-partnered bladder cancer drug Padcev. Also, during the recent ASCO meeting, Pfizer released updated phase 3 results for the ALK inhibitor Lorbrena in newly diagnosed advanced ALK-positive non-small cell lung cancer. Results show that 60% of patients who were given Lorbrena in the CROWN trial stayed alive without disease progression, as opposed to only 8% of patients who received Pfizer’s old ALK drug Xalkori. Lorbrena also caused a 94% reduction in the progression of brain metastases or an 81% reduction in the risk of disease progression or death compared to Xalkori. More updates on what we had eyes on: https://lnkd.in/g6yiS4vt
Eyes on Oncology, Anti-Virals, and Consumer Products
pharmatell.com
To view or add a comment, sign in
-
In this blog, Bryce Davies, IQVIA’s Head of Asia Early Phase Oncology Academy, discusses how IQVIA’s EPON is paving the way for increased efficiency in early phase oncology research – offering stable relationships, detailed site information, and expertly aligned processes. Read now. https://bit.ly/48X9Jyw #EPON #EarlyPhase #Oncology
IQVIA's EPON Paves the Way for More Efficient Early Phase Oncology Research
iqvia.com
To view or add a comment, sign in
-
AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encouraging results from an ongoing clinical trial on datopotamab deruxtecan, a #drug aimed at treating breast cancer. The pharma giant reported a "statistically significant and clinically meaningful improvement" in progression-free survival rates compared with traditional chemotherapy treatments. Sean Conroy at Shore Capital said: "This was another pivotal readout for datopotamab deruxtecan and could reinvigorate sentiment about this #drug broader potential to replace systemic #chemotherapy across a range of cancers while also providing another important read on safety." #LSE #AZN More at #Proactive #ProactiveInvestors http://ow.ly/34Uq104VaOa
AstraZeneca breast cancer drug gives pharma giant £5bn boost
proactiveinvestors.co.uk
To view or add a comment, sign in
-
At this year’s American Society of Clinical Oncology annual meeting, experts from AON presented an abstract on the impact of regional clinical pharmacists on selecting the most cost-effective biosimilar products. Through the biosimilar substitution program, AON’s practices saved $56.5 million in 2022. Oncology biosimilars have seen the strongest adoption. Of the 37 FDA-approved biosimilars on the market in the United States, 22 of them have cancer indications.
Biosimilars Had a Huge Impact on Total Cost of Care, Says AON’s Christine Pfaff
ajmc.com
To view or add a comment, sign in
-
| X-Microlabs intern'24 | MBA Pharmaceutical Management'25 - IIHMR University,Jaipur | Bachelor of Pharmacy'23 | GPAT Qualified 2023| NIPER AIR- 839 | In Top 5 university Topper|
✅️ When we check out the top cancer drugs, we notice some interesting trends. 👉Sure! Merck is really big in treating cancer, mainly because of one medicine called "KEYTRUDA." It makes up about 90% of their sales in this area. On the other hand, Novartis isn't in the top 15 for individual cancer drugs, but because they have lots of different medicines for different things(Portfolio) , they're still the 6th biggest in cancer treatment worldwide. 👉The top-selling drugs mostly come from the US and Europe, but Japanese and Chinese companies are making their mark too. 👉For some companies, cancer drugs are their main focus, but for others, they're just part of a bigger picture." For eg, For some companies like BeiGene, it's their main focus, while for others like Eli Lilly, it's strong but not dominant compared to their other therapeutic areas." 💫Hers are the top 15 Oncology drugs by worldwide sales in 2023.💫 🟢" Keytruda by Merck" emerged as the top-selling product with sales reaching $25 billion.🟢
To view or add a comment, sign in
-
-
Please find here a minireview together with Marlena Surówka focusing on the recently approved BsAbs in and outside of oncology, their MOAs and the formats applied to make them as well as a brief outlook of the field https://lnkd.in/ebsA_mVX
A pivotal decade for bispecific antibodies?
tandfonline.com
To view or add a comment, sign in
-
Clinical Biomarkers Oncology, Asset and Disease Area Biomarker Strategy, Biomarker Technologies, Cross Functional Leadership, Talent Development
🚀 Exciting breakthroughs in cancer therapy! This article delves into the world of bispecific antibodies (bsAbs), highlighting recent approvals & future prospects in solid tumors. Overcoming challenges like tumor penetration, T cell trafficking, resistance mechanisms (e.g., downregulation of target antigens, activation of alternative pathways), and immunosuppressive tumor microenvironments is key. #CancerResearch #Immunotherapy 🧬🔬
Please find here a minireview together with Marlena Surówka focusing on the recently approved BsAbs in and outside of oncology, their MOAs and the formats applied to make them as well as a brief outlook of the field https://lnkd.in/ebsA_mVX
A pivotal decade for bispecific antibodies?
tandfonline.com
To view or add a comment, sign in
-
The FDA Oncology Center of Excellence (OCE) Project 5 in 5 is a crowdsourcing initiative to ultimately identify 5 clinically relevant questions that can be answered through use of pragmatic clinical trials, using FDA-approved oncology therapies, over the next 5 years. https://lnkd.in/e2mun4uM
Project 5 in 5
fda.gov
To view or add a comment, sign in
-
NEW: Hui Tan and Viktor Danev take a look at recent #HTA decisions in Europe and offer a perspective on the UK #Cancer Drugs Fund, potentially helpful for #biopharma companies planning to enter the UK market with #oncology product(s). >> https://lnkd.in/gDfg7fJj
July 2023 HTA Decisions & the UK Cancer Drugs Fund - Blue Matter Consulting
https://bluematterconsulting.com
To view or add a comment, sign in
-
In this blog, Bryce Davies, IQVIA’s Head of Asia Early Phase Oncology Academy, discusses how IQVIA’s EPON is paving the way for increased efficiency in early phase oncology research – offering stable relationships, detailed site information, and expertly aligned processes. Read now. https://bit.ly/3tBJnCu #EPON #EarlyPhase #Oncology
IQVIA's EPON Paves the Way for More Efficient Early Phase Oncology Research
iqvia.com
To view or add a comment, sign in